Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM4 | P08173 | 1/20 | 0.44 |
| ▸ | F2 | P00734 | 5/20 | 0.44 |
| ▸ | F10 | P00742 | 2/20 | 0.44 |
| ▸ | PLG | P00747 | 2/20 | 0.44 |
| ▸ | PLAU | P00749 | 2/20 | 0.44 |
| ▸ | ST14 | Q9Y5Y6 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | ITGB3 | P05106 | 3/20 | 0.43 |
| ▸ | ITGA2B | P08514 | 3/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | ACE | P12821 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CCR2 | P41597 | 2/20 | 0.40 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2903664 | 1.00 | CHRM4 (0.44) | CHRM4F2F10PLGPLAU | |
| SCHEMBL2898000 | 1.00 | CHRM4 (0.44) | CHRM4F2F10PLGPLAU | |
| SCHEMBL3760950 | 0.91 | F2 (0.46) | CHRM4F2F10PLGPLAU | |
| SCHEMBL2919067 | 0.91 | F2 (0.46) | CHRM4F2F10PLGPLAU | |
| SCHEMBL2903708 | 0.90 | ITGB3 (0.46) | CHRM4F2F10PLGPLAU | |
| SCHEMBL2903709 | 0.90 | ITGB3 (0.46) | CHRM4F2F10PLGPLAU | |
| SCHEMBL3751375 | 0.90 | CCR2 (0.42) | CHRM4F2F10PLGPLAU | |
| SCHEMBL2905205 | 0.90 | CCR2 (0.42) | CHRM4F2F10PLGPLAU | |
| SCHEMBL2905209 | 0.90 | CCR2 (0.42) | CHRM4F2F10PLGPLAU | |
| SCHEMBL2903784 | 0.89 | CALCRL (0.48) | F10MEN1ALDH1A1KMT2AITGB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100298299-A1 | NON-PEPTIDE DERIVATIVES AS BRADYKININ B1 ANTAGONISTS | RICHTER GEDEON NYRT. (HU) | 2010-11-25 | — | — | US | claimed |
| EP-2215055-A1 | NEW NON-PEPTIDE DERIVATIVES AS BRADYKININ B1 ANTAGONISTS | Richter Gedeon Nyrt. (HU) | 2010-08-11 | — | — | EP | claimed |
| WO-2009053763-A1 | NEW NON-PEPTIDE DERIVATIVES AS BRADYKININ BL ANTAGONISTS | RICHTER GEDEON NYRT. (HU) | 2009-04-30 | — | — | WO | claimed |
| US-20100298299-A1 | NON-PEPTIDE DERIVATIVES AS BRADYKININ B1 ANTAGONISTS | RICHTER GEDEON NYRT. (HU) | 2010-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298299-A1 | NON-PEPTIDE DERIVATIVES AS BRADYKININ B1 ANTAGONISTS | BDKRB1, BDKRB2, NPBWR1 | CHRM4 879/4885F2 66/4885F10 319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.